Association between diabetes or antidiabetic therapy and lung cancer: A meta‐analysis

Wang, Zhida; Bao, Cuiping; Su, Cheng; Xu, Weili; Luo, Huimin; Chen, Liming; Qi, Xiaojuan

doi:10.1111/jdi.12112

Cited by 11 publications

(6 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, an early study in Korean men showed that hypertension was not an independent risk factor in lung cancer mortality [ 40 ]. Similarly, result of a meta-analysis of 14 cohort studies also concluded that diabetes was not associated with lung cancer risk [ 41 ]. A recent cohort study showed that the potential impact of diabetes on the risk of lung cancer may be modified by smoking status of the patients, and diabetes may have minimal impact on lung cancer development in the never-smoking population [ 42 ].…”

Section: Discussionmentioning

confidence: 99%

Metabolic syndrome and the incidence of lung cancer: a meta-analysis of cohort studies

Qiao

et al. 2020

Diabetol Metab Syndr

View full text Add to dashboard Cite

Background Metabolic syndrome (MetS) has been related to the pathogenesis of variety categories of cancers. This meta-analysis aimed to determine the association between MetS and the incidence of lung cancer. Methods Relevant cohort studies were identified by search of PubMed, Embase, and Cochrane’s Library databases. Cochrane’s Q test and I2 statistic were used to analyze the heterogeneity. Random-effect model which incorporates the potential heterogeneity was used for the meta-analysis. Results Five cohort studies with 188,970 participants were included. A total of 1,295 lung cancer cases occurred during follow-up. Meta-analyses showed that neither MetS defined by the revised NCEP-ATP III criteria (hazard ratio [HR]: 0.94, 95% confidence interval [CI]: 0.84 to 1.05, p = 0.25; I2 = 0) nor the IDF criteria (HR: 0.82, 95% CI: 0.61 to 1.11, p = 0.20; I2 = 0) was associated with an affected risk of lung cancer. Subgroup analyses showed consistent results in women and in men, in studies performed in Asian and non-Asian countries, and in prospective and retrospective cohorts (p all > 0.05). Meta-analysis limited to studies with the adjustment of smoking status also showed similar results (HR: 0.91, 95% CI: 0.80 to 1.05, p = 0.21; I2 = 0). No publication bias was detected based on the Egger regression test (p = 0.32). Conclusions Current evidence from cohort studies does not support that MetS is an independent risk factor for the incidence of lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Metabolic syndrome and the incidence of lung cancer: a meta-analysis of cohort studies

Qiao

et al. 2020

Diabetol Metab Syndr

View full text Add to dashboard Cite

show abstract

“…Several original studies and evidence summaries have evaluated at least one component or one drug relevant to this research question 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 . However, informed decision making requires a comprehensive summary of all available diabetes treatments that allows comparing the various options in terms of their effect on cancer risk and mortality.…”

mentioning

confidence: 99%

Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies

Wu¹,

Zhu

Prokop

et al. 2015

Sci Rep

134

114

View full text Add to dashboard Cite

Different anti-diabetic medications (ADMs) may modify cancer risk and mortality in patients with diabetes. We conducted a systematic review and meta-analysis to estimate the magnitude of association and quality of supporting evidence for each ADM. A total of 265 studies (44 cohort studies, 39 case-control studies, and 182 randomized controlled trials (RCT)) were identified, involving approximately 7.6 million and 137,540 patients with diabetes for observational studies and RCTs, respectively. The risk of bias overall was moderate. Meta-analysis demonstrated that the use of metformin or thiazolidinediones was associated with a lower risk of cancer incidence (RR = 0.86, 95% CI 0.83-0.90, I2 = 88.61%; RR = 0.93, 95% CI 0.91-0.96, I2 = 0.00% respectively). On the other hand, insulin, sulfonylureas and alpha glucosidase inhibitor use was associated with an increased risk of cancer incidence (RR = 1.21, 95% CI 1.08-1.36, I2 = 96.31%; RR = 1.20, 95% CI 1.13-1.27, I2 = 95.02%; RR = 1.10, 95% CI 1.05-1.15, I2 = 0.00% respectively). Use of other types of ADMs was not significantly associated with cancer risk. This study indicates that some ADMs may modify the risk of cancer in individuals with diabetes. Knowledge of this risk may affect the choice of ADM in individuals concerned about cancer or at increased risk for cancer.

show abstract

“…However, an early study in Korean men showed that hypertension was not an independent risk factor in lung cancer mortality [33]. Similarly, result of a meta-analysis of 14 cohort studies also indicated that no association between diabetes and lung cancer risk exists [34]. Taken together, only higher triglyceride of MetS components may relate to the higher risk of lung cancer, and the association between MetS and subsequent risk of lung cancer may depend on the predominance of the distribution of the components.…”

Section: Discussionmentioning

confidence: 99%

Metabolic syndrome and the incidence of lung cancer: a meta-analysis of cohort studies

Dong¹,

Yang²

2018

Oncotarget

View full text Add to dashboard Cite

Background: Metabolic syndrome (MetS) has been related to the pathogenesis of variety categories of cancers. This meta-analysis aimed to determine the association between MetS and the incidence of lung cancer.Materials and Methods: Relevant cohort studies were identified by searching of PubMed and Embase databases. Cochrane's Q test and I 2 statistic were used to analyze the heterogeneity. Random effect model was used for the meta-analysis.Results: Five cohort studies with 188,970 participants and 1,295 lung cancer cases during follow-up were included. No significant association between MetS and lung cancer incidence was found in studies that MetS was defined by the revised NCEP-ATP III criteria (hazard ratio [HR]: 0.94, 95% confidence interval [CI]: 0.84 to 1.05, p = 0.25; I 2 = 0), or IDF criteria (HR: 0.82, 95% CI: 0.61 to 1.11, p = 0.20; I 2 = 0). Results were consistent in male and female participants, or in those smoking status was adjusted (HR: 0.91, 95% CI: 0.80 to 1.05, p = 0.21; I 2 = 0). Sensitivity analyses omitting one study at a time did not significantly change the results. No publication bias was detected based on the Egger regression test (p = 0.32).Conclusions: Presence of MetS does not significantly influence the subsequent incidence of lung cancer.

show abstract

Association between diabetes or antidiabetic therapy and lung cancer: A meta‐analysis

Cited by 11 publications

References 47 publications

Metabolic syndrome and the incidence of lung cancer: a meta-analysis of cohort studies

Metabolic syndrome and the incidence of lung cancer: a meta-analysis of cohort studies

Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies

Metabolic syndrome and the incidence of lung cancer: a meta-analysis of cohort studies

Contact Info

Product

Resources

About